FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris
Basel, 14 February 2018 FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris Pemphigus vulgaris (PV) is a life-threatening, autoimmune condition with limited treatment options1 The FDA previously granted Breakthrough Therapy Designation and Orphan Drug Designation for MabThera/Rituxan in PV Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food... Read more